Nuevos biomarcadores usados en el diagnóstico del daño renal en condiciones de estrés oxidativo
Resumen
En este estudio se muestra la importancia de los biomarcadores candidatos a predictores de enfermedad renal, mediante los resultados y evidencias obtenidas en los últimos años, así como también, la relación directa con el estrés oxidativo. La Enfermedad Renal Crónica (ERC), se define como la pérdida progresiva de la funcionalidad del riñón y una disminución brusca del filtrado glomerular <60ml/min/1.73m2, durante 3 o más meses, acompañada por anormalidades renales, de tipo estructural, funcional o ambas, con acumulo de productos nitrogenados y una alteración en la homeostasis hidroelectrolítica con el paso de los meses e incluso años. Representando el cuarto lugar en prevalencia a nivel mundial.
Descargas
Citas
Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014; 7:75-88.
Kovesdy C, Susan F y Zoccali C, Obesity and kidney disease: Hidden consequences of the epidemic. J Ren Nutr 2017 27 (2): 75-77.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Platther B, Saran R, Wang AY, Yang CW. Chronic Kidney Disease: Global dimensión and perspectives. The Lancet 2013; 382(9888): 260-72.
Monedero P, Garcia Fernandez N, Perez Valdivieso J.R, Vives M, Lavilla J. Acute kidney injury. Rev Esp Anestesiol Reanim 2011; 58: 365-374.
Martínez A, Górriz J, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernánd J-, José L. Caro L, Mazón P, Montañés R, Morales F, Muñoz M, Velasco P, Santiago A, Sánchez M, Suárez C, Tranche S. Consensus document for detection and management of chronic kidney disease. Nefrología 2014; 34 (2):243-62.
Washington, DC, 2014 (OPS/OMS). Recuperado de: https://www.paho.org/hq/index.php?option=com_content&view=article&id=9379:2014-kidney-disease-rising-among-seniors-diabetes-hypertension&Itemid=1926&lang=es
Orozco R. Recognition and prevention of chronic kidney disease (CKD). Revista médica clínica los condes 2010; 21:779-789.
Bjornstad P, Pyle L, Cherney D.Z.I, Johnson RJ, Sippl R, Wong R, Rewers M, Snell-bergeon JK. Plasma biomarkrs improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol Dial Transplant 2018; 33: 1189-1196.
Csiky B, Sági B, Peti A, Lakatos O, Prémusz V, Sulyok E. The Impact of Osteocalcin, Osteoprotegerin and Osteopontin on Arterial Stiffness in Chronic Renal Failure Patients on Hemodialysis. Kidney Blood Press Res 2017; 6:1312 1321.
Chapman J, Miles PD, Ofrecio JM, Neels JG, Yu JG, Resnik JL Wilkes J, Talukdar S, Thapar D, Jhonson K, Sears DD. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLos ONE 2010; 5(11): 139-59.
Kiefer FW, Neschen S, Pfau B, Legerer P, Neuhofer A, Kahne M, Hrabe de Angelis M, Schlederer M, Mair M, Kener L, Plutzky J, Zeyda M, Stulnig TM. Osteopontin defiiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011; 54(8): 2132–2142.
Wen Y, Jeong S, Xia Q, Kong X. Role of osteopontin in liver diseases. International Journal of Biological Sciences 2016; 12(9): 1121–1128.
Kothari AN, Arff ML, Chang V, Blackwel RH, Syn WK, Zhang J, Mi Z, Kuo PC. Osteopontin a master regulator of epithelial mesenchymal transition. Journal of Clinical Medicine 2016; (5) 4-39.
Barreto R, Guevara M. Biomarkers of acute kidney injury: a « trending topic » in cirrhosis Gastroenterol Hepatol. 2013; 6:407-21.
Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018; 59:17-24.
Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22:549-553.
Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, Jensen GB, Kjoller E, Winkel P, Flyvbjerg A, Gluud C, Claricor TG. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. Scand J Clin Lab Invest 2014; 74:657-664.
Nascimento MM, Hayashi SY, Riella MC, Lindholm B. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res 2014; 47 (11): 995-1002.
Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E: Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2015; 438:401-414.
Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, Hansis-Diarte A, Jenkinson C, Tripathy D, Folli F. The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetol 2018; 2:139-148.
Lenora J, Ivaska KK, Obrant KJ, Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007; 18: 1297-1305.
Zhang Y, Qi L, Gu W, Yan Q, Dai M, Shi J, Zhai Y, Chen Y, Liu J, Wang W, Ning G, Hong J: Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults. Am J Cardiol 2010; 106: 1461-1465.
Bao Y, Zhou M, Lu Z, Li H, Wang Y, Sun L, Gao M, Wei M, Jia W: Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men. Clin Endocrinol 2011; 75:196-201.
Osorio A, Ortega E, Torres JM, Sanchez P, Ruiz-Requena E. Biochemical markers of vascular calcification in elderly hemodialysis patients. Mol Cell Biochem 2013; 374:21-27.
Lerchbaum E, Schwetz V, Pilz S, Grammer TB, Look M, Boehm BO, Obermayer Pietsch B, Marz W Association of bone turnover markers with mortality in men referred to coronary angiography. Osteoporos Int 2013; 24:1321-1332.
Lee HG, Choi HY, Bae JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int. 2014; 86 (6):1079-1081.
Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers. Pediatr Nephrol 2015; 4:677-85.
Uwaezuoke SN, Ayuk AC, Muoneke VU, Mbanefo NR. Chronic kidney disease in children: Using novel biomarkers as predictors of disease. Saudi J Kidney Dis Transpl 2018; 4: 775-784.
Cen C, Aziz M, Yang WL, Nicastro JM, Coppa GF, Wang P. Osteopontin Blockade Attenuates Renal Injury After Ischemia Reperfusion by Inhibiting NK Cell Infiltration. Shock. 2017; 1: 52-60.
Roos JF, Doust J, Tett SE, Tett SE, Carl MJ, Kirkpatrick CMJ. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children a meta analysis. Clin Biochem 2007; 40:383-91.
Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med. 2007; 45:1232-6.
Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens 2015; (3): 295-300.
Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, Castaldo D, De Micco F, Ricciardelli B, Colombo A. Cystatin C and contrast-induced acute kidney injury. Circulation 2010; 19:2117-22.
Askenazi DJ, Ambalavanan N, Goldstein SL. Acute Kidney injury in critically ill newborns: What do we need to learn? Pediatric Nephrology. 2009; 24 (2):265-74.
Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Yi Li J, Weiss S, Mishra Y, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D´Agaty V, Debaragn P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610-21.
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarjan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365:1231-8.
Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceuticals (Basel) 2018; 4: 2-15.
Castillo R, Huerta P, Carrasco R, Ramón R. Estrés oxidativo y daño renal. CIMEL Ciencia e Investigación Médica Estudiantil Latinoamericana 2003; 1:44-53.
Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998; 3:848-56.
Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 7:2006-16.
Gérard-Monnier D, Erdelmeier I, Régnard K, Moze-Henry N, Yadan JC, Chaudière J. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4 hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem Res Toxicol 1998; 10:1176-83.
Oh JA, Shin HS. Simple and sensitive determination of malondialdehyde in human urine and saliva using UHPLC-MS/MS after derivatization with 3,4 diaminobenzophenone. J Sep Sci 2017; 20:3958-3968.
Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids 2012; 2012:1-10.
Noce A, Fabrini R, Dessì M, Bocedi A, Santini S, Rovella V, Pastore A, Tesauro M, Bernardini S, Di Daniele N, Ricci G. Erythrocyte glutathione transferase activity: a possible early biomarker for blood toxicity in uremic diabetic patients. Acta Diabetol 2014; 51(2): 219-24.
Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol 1990; 186: 287-301.
Anand U, Anand CV. Myeloperoxidase: a new twist to an old tale. India Clin Biochem 2012; 27(2):107-9.
Sokolov AV, Kostevich VA, Runova OL, Gorudko IV, Vasilyev VB, Cherenkevich SN, et al. Proatherogenic modification of LDL by surface-bound myeloperoxidase. Sokolov AV, Chem Phys Lipids 2014; 180:72-80.
